ArticleLenvatinib expands its reach into renal cell carcinomaAuthor:MD; report prepared by Jane de LartiguePublish date: April 17, 2017The US Food and Drug Administration (FDA) expanded the approval of the multitargeted tyrosine kinase inhibitor lenvatinib to a second indication in...Read More
